Quantedge Capital Pte Ltd Has $7.67 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Quantedge Capital Pte Ltd trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 20.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 267,755 shares of the specialty pharmaceutical company's stock after selling 70,445 shares during the period. Collegium Pharmaceutical comprises 2.8% of Quantedge Capital Pte Ltd's portfolio, making the stock its 6th largest position. Quantedge Capital Pte Ltd owned 0.83% of Collegium Pharmaceutical worth $7,671,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of COLL. New Age Alpha Advisors LLC purchased a new position in Collegium Pharmaceutical during the 4th quarter valued at about $40,000. KBC Group NV raised its holdings in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares during the period. Finally, FORA Capital LLC purchased a new stake in Collegium Pharmaceutical in the fourth quarter worth approximately $223,000.

Analyst Ratings Changes

COLL has been the subject of several recent research reports. StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler restated a "neutral" rating and set a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Finally, Needham & Company LLC restated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Collegium Pharmaceutical Price Performance

Shares of COLL stock traded down $0.44 on Monday, hitting $29.79. 97,359 shares of the stock traded hands, compared to its average volume of 428,377. The firm has a market cap of $957.24 million, a price-to-earnings ratio of 12.85 and a beta of 0.63. Collegium Pharmaceutical, Inc. has a 52 week low of $23.23 and a 52 week high of $42.29. The firm has a 50 day simple moving average of $28.12 and a two-hundred day simple moving average of $29.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $177.76 million for the quarter, compared to the consensus estimate of $174.96 million. During the same quarter in the prior year, the company posted $1.45 EPS. Collegium Pharmaceutical's revenue was up 22.7% compared to the same quarter last year. As a group, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 10,445 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the sale, the chief financial officer now owns 165,246 shares of the company's stock, valued at $4,959,032.46. This trade represents a 5.95% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is owned by insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.